Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043823 | 0.85 | POLB (0.39) | EPHX2RAB9ANPC1 | |
| SCHEMBL6154511 | 0.71 | PTGS2 (0.46) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6154189 | 0.71 | PTGS2 (0.46) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5046250 | 0.71 | NPC1 (0.42) | EPHX2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5040616 | 0.70 | MAOB (0.38) | KMT2ARAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL6154092 | 0.69 | PTGS2 (0.47) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5039417 | 0.68 | TSHR (0.40) | ALDH1A1LMNA | |
| SCHEMBL6318672 | 0.67 | TDP1 (0.45) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL5035885 | 0.66 | LTA4H (0.46) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL30674771 | 0.65 | NFE2L2 (0.70) | KDM4EMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677745-A4 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1677745-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | RENOVIS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005037208-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | NLN, NQO1, OPRL1 | KDM4E 4105/4885MEN1 1676/4885KMT2A 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.